Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006

Oxygen-Ozone Treatment in Bisphosphonate Related Osteonecrosis of the Jaw: A Case Report

“…Some authors reported cases of spontaneous recovery after the O 2 /O 3 administration without the need for any surgical procedure [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19]. Unfortunately our patient also needed for surgical intervention.…”

“…Patients treated with BF therapy have more chances to develop BRONJ, depending on the doses, the bioavailability of the drug and the comorbidity [17].…”

Bisphosphonate-related Osteonecrosis of the Jaws: An Update on Clinical, Pathological and Management Aspects

“…Nitrogencontaining bisphosphonates (intravenous zoledronic acid or pamidronate), together with other treatment options, are used widely for the treatment of these negative skeletal events [1]. In 2003, after an alert initial observation by Wang et al [2] at the University of California San Francisco, Rosenberg and Ruggiero [3], Marx [4] and Migliorati [5] have reported unusual findings of osteomyelitis-like lesions of the jaws in a set of patients affected by multiple myeloma and metastatic bone disease; subsequently, several papers have confirmed the initial observations and called this condition bisphosphonaterelated osteonecrosis of the jaws (BRONJ) [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]. All the initial observations have pointed to the potential role of the intravenously administered bisphosphonates such as pamidronate and zoledronate.…”

“…The duration of bisphosphonate therapy is also an important factor which relates to the likelihood of developing BRONJ. In addition, the more potent nitrogen-containing bisphosphonates, such as pamidronate and zolendronate, are more often associated with the development of BRONJ than the oral bisphosphonate formulations [16][17][18][19][20][21][22][23][24][25]. An important paper published recently by Corso et al [44] has highlighted the importance of reducing the schedule of zolendronic acid in order to lower the risk of BRONJ in patients with multiple myeloma.…”

“…In order to establish rational treatment guidelines and collect clinical information to assess the prognosis in patients with BRONJ, a working definition and staging system have been proposed by some researchers as well as associations such as the American Association of Oral and Maxillofacial Surgeons (AAOMS), the Novartis Pharmaceuticals Corporation and others [19,24,53]. To distinguish BRONJ from other delayed healing entities, the AAOMS [53] has adopted the following working definition.…”